Literature DB >> 3010011

Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study.

S M Crawford, R Buckman.   

Abstract

Thirty-two patients were entered into a double blind trial of antiemetic support in patients being treated with cisplatin. Patients were allocated to receive either oral nabilone (1 mg 8 hourly) or intravenous metoclopramide (1 mg kg-1 3 hourly) in random order over 4 courses. There was no difference between the two treatments in the overall incidence or severity of vomiting, although a subgroup of patients enjoyed a substantial reduction in episodes of vomiting whilst receiving metoclopramide. Side-effects were predictable from the pharmacology of the drugs.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3010011     DOI: 10.1007/bf02934575

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  4 in total

1.  Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy.

Authors:  T S Herman; L H Einhorn; S E Jones; C Nagy; A B Chester; J C Dean; B Furnas; S D Williams; S A Leigh; R T Dorr; T E Moon
Journal:  N Engl J Med       Date:  1979-06-07       Impact factor: 91.245

2.  Antiemetics and cytotoxic drugs.

Authors:  J R Trounce
Journal:  Br Med J (Clin Res Ed)       Date:  1983-01-29

3.  Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol.

Authors:  R J Gralla; L B Tyson; L A Bordin; R A Clark; D P Kelsen; M G Kris; L B Kalman; S Groshen
Journal:  Cancer Treat Rep       Date:  1984-01

4.  Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting.

Authors:  R J Gralla; L M Itri; S E Pisko; A E Squillante; D P Kelsen; D W Braun; L A Bordin; T J Braun; C W Young
Journal:  N Engl J Med       Date:  1981-10-15       Impact factor: 91.245

  4 in total
  12 in total

Review 1.  Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review.

Authors:  M R Tramèr; D Carroll; F A Campbell; D J Reynolds; R A Moore; H J McQuay
Journal:  BMJ       Date:  2001-07-07

Review 2.  Regulation of nausea and vomiting by cannabinoids.

Authors:  Linda A Parker; Erin M Rock; Cheryl L Limebeer
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

3.  Tetrahydrocannabinolic acid reduces nausea-induced conditioned gaping in rats and vomiting in Suncus murinus.

Authors:  E M Rock; R L Kopstick; C L Limebeer; L A Parker
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

4.  Anticipatory nausea in animal models: a review of potential novel therapeutic treatments.

Authors:  Erin M Rock; Cheryl L Limebeer; Linda A Parker
Journal:  Exp Brain Res       Date:  2014-05-04       Impact factor: 1.972

Review 5.  The therapeutic potential of cannabis and cannabinoids.

Authors:  Franjo Grotenhermen; Kirsten Müller-Vahl
Journal:  Dtsch Arztebl Int       Date:  2012-07-23       Impact factor: 5.594

Review 6.  [Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research].

Authors:  A Du Bois
Journal:  Med Klin (Munich)       Date:  1998-01

Review 7.  [Review of cannabinoids in the treatment of nausea and vomiting].

Authors:  L Radbruch; F Nauck
Journal:  Schmerz       Date:  2004-08       Impact factor: 1.107

8.  Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system.

Authors:  Keith A Sharkey; Nissar A Darmani; Linda A Parker
Journal:  Eur J Pharmacol       Date:  2013-11-01       Impact factor: 4.432

9.  A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting.

Authors:  Mark A Ware; Paul Daeninck; Vincent Maida
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423

10.  Medical marijuana utilization in gynecologic cancer patients.

Authors:  Julia Fehniger; Allison L Brodsky; Arum Kim; Bhavana Pothuri
Journal:  Gynecol Oncol Rep       Date:  2021-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.